Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Q1 Revenues Jump 80 Percent

NEW YORK, May 1 – Ciphergen Biosystems reported Tuesday an 80 percent increase in first-quarter revenues to $2.7 million from $1.5 million in the year-ago quarter.

The company attributed the increase to greater sales of its ProteinChip systems and arrays in addition to service revenue from their Biomarker Discovery Centers. The growth represents “continued progress in our mission of enabling benchtop biologists to perform proteomics research," William Rich, CEO of Ciphergen, said in a statement.

The Fremont, Calif.,-based company said its total expenses rose to $9.1 million from $3.7 million for the first quarter of 2000. Of the 2001 expenses, $1.5 million was deferred stock compensation versus $900,000 for the year-ago quarter. Research and development expenses increased to $2.6 million, from $1 million in 2000 and general and administrative expenses were up to $3.4 million from $1.1 million in the year-ago quarter.

First-quarter net losses were $6 million, or 23 cents per share, computed from 26.3 million shares, compared with $2.7 million, or 41 cents a share for 6.5 million shares, in the year ago period.

As of the end of March, the company had $103.2 million in cash, cash equivalents, and long-term investments.

Ciphergen said that following a lag in its marketing efforts, it now expected to maintain quarter-to-quarter revenue growth of between 80 and 110 percent for the remainder of the year. However, the company also foresees the possibility of downturn.

“We believe that the effect of the ramp-up in our sales force hasn't yet been fully reflected in our sales,” said Rich. “In addition, we were clearly not immune to the overall economic environment which has caused certain of our prospective customers to be cautious in their capital goods purchases.”

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.